2- (2- (4- phenoxy- 2- propylphenoxy)ethyl)indole- 5- acetic acid

structure in first source

Also Known As:

2-PPPE-IAA; PPEIA cpd

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid: 1
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Acetates: 4994
      - 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid: 1
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid: 1

Experts

1.	Ernsberger, Paul: 1 article (07/2005)
2.	Friedman, Jacob E: 1 article (07/2005)
3.	Shao, J: 1 article (07/2005)
4.	Velliquette, Rodney A: 1 article (07/2005)
5.	Zhang, Bei B: 1 article (07/2005)

Related Diseases

1.	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/01/2005 - "Insulin resistance clusters with hyperlipidemia, impaired glucose tolerance, and hypertension as metabolic syndrome X. We tested a low molecular weight insulin receptor activator, demethylasterriquinone B-1 (DMAQ-B1), and a novel indole peroxisome proliferator-activated receptor gamma agonist, 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid (PPEIA), in spontaneously hypertensive obese rats (SHROB), a genetic model of syndrome X. Agents were given orally for 19 days. "
2.	Glucose Intolerance 07/01/2005 - "Insulin resistance clusters with hyperlipidemia, impaired glucose tolerance, and hypertension as metabolic syndrome X. We tested a low molecular weight insulin receptor activator, demethylasterriquinone B-1 (DMAQ-B1), and a novel indole peroxisome proliferator-activated receptor gamma agonist, 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid (PPEIA), in spontaneously hypertensive obese rats (SHROB), a genetic model of syndrome X. Agents were given orally for 19 days. "
3.	Insulin Resistance 07/01/2005 - "Insulin resistance clusters with hyperlipidemia, impaired glucose tolerance, and hypertension as metabolic syndrome X. We tested a low molecular weight insulin receptor activator, demethylasterriquinone B-1 (DMAQ-B1), and a novel indole peroxisome proliferator-activated receptor gamma agonist, 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid (PPEIA), in spontaneously hypertensive obese rats (SHROB), a genetic model of syndrome X. Agents were given orally for 19 days. "
4.	Hypertension (High Blood Pressure) 07/01/2005 - "Insulin resistance clusters with hyperlipidemia, impaired glucose tolerance, and hypertension as metabolic syndrome X. We tested a low molecular weight insulin receptor activator, demethylasterriquinone B-1 (DMAQ-B1), and a novel indole peroxisome proliferator-activated receptor gamma agonist, 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid (PPEIA), in spontaneously hypertensive obese rats (SHROB), a genetic model of syndrome X. Agents were given orally for 19 days. "
5.	Hyperlipidemias (Hyperlipidemia) 07/01/2005 - "Insulin resistance clusters with hyperlipidemia, impaired glucose tolerance, and hypertension as metabolic syndrome X. We tested a low molecular weight insulin receptor activator, demethylasterriquinone B-1 (DMAQ-B1), and a novel indole peroxisome proliferator-activated receptor gamma agonist, 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid (PPEIA), in spontaneously hypertensive obese rats (SHROB), a genetic model of syndrome X. Agents were given orally for 19 days. "

Related Drugs and Biologics

1.	Insulin Receptor
2.	PPAR-gamma Agonists
3.	L 783281
4.	indole